[
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
    "summary": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
    "url": "https://finnhub.io/api/news?id=44d1226b7a478146b50c8ca551ccabf95d5540c7da8f493298f315b814af5b63",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753893240,
      "headline": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
      "id": 136158114,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
      "url": "https://finnhub.io/api/news?id=44d1226b7a478146b50c8ca551ccabf95d5540c7da8f493298f315b814af5b63"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Appreciation Fund Q2 2025 Commentary",
    "summary": "ClearBridge Appreciation Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=999201e24986281244a91487c0d473ae55541143f2d26127d85e965493f010fb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753871700,
      "headline": "ClearBridge Appreciation Fund Q2 2025 Commentary",
      "id": 136131190,
      "image": "",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=999201e24986281244a91487c0d473ae55541143f2d26127d85e965493f010fb"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge All Cap Growth Portfolios Q2 2025 Commentary",
    "summary": "ClearBridge All Cap Growth Portfolios Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=82059148984f804b92ae0eb7934af07618f1e1ea7768cffafb6545fe06067ebf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753868700,
      "headline": "ClearBridge All Cap Growth Portfolios Q2 2025 Commentary",
      "id": 136130393,
      "image": "",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=82059148984f804b92ae0eb7934af07618f1e1ea7768cffafb6545fe06067ebf"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific",
    "summary": "The global Formulation Development Outsourcing Market is projected to grow from US$ 33.6 billion in 2024 to US$ 64.74 billion by 2033, at a CAGR of 7.56%. Key growth drivers include rising R&D costs, demand for specialized knowledge, complex regulations, and an expanding pharmaceutical industry. As pharmaceutical and biotech companies increasingly rely on contract development and manufacturing organizations (CDMOs) for integrated, end-to-end services, markets in North America, Europe, and the ra",
    "url": "https://finnhub.io/api/news?id=d5b478dc239482f4a68c45ce6a3fde2cb1632054ef994b3ec660d9a754d172df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753867560,
      "headline": "Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific",
      "id": 136129913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The global Formulation Development Outsourcing Market is projected to grow from US$ 33.6 billion in 2024 to US$ 64.74 billion by 2033, at a CAGR of 7.56%. Key growth drivers include rising R&D costs, demand for specialized knowledge, complex regulations, and an expanding pharmaceutical industry. As pharmaceutical and biotech companies increasingly rely on contract development and manufacturing organizations (CDMOs) for integrated, end-to-end services, markets in North America, Europe, and the ra",
      "url": "https://finnhub.io/api/news?id=d5b478dc239482f4a68c45ce6a3fde2cb1632054ef994b3ec660d9a754d172df"
    }
  },
  {
    "ts": null,
    "headline": "Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic",
    "summary": "The global Drug Abuse Testing Market is set to surge, reaching $12.77 billion by 2033 from $6.64 billion in 2024, experiencing a CAGR of 7.54% between 2025-2033. This growth is driven by rising drug abuse rates, enhanced public awareness, and strict laws. Technological advancements in testing and an increased emphasis on preventative healthcare further boost the market. Key product and service segments include analyzers, rapid testing devices, and laboratory services, with urine tests dominating",
    "url": "https://finnhub.io/api/news?id=7fb19a3884e7caa6c6929cccbbce9cc63449259a8753cad5a3ddeaaabe0e0e43",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753866480,
      "headline": "Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic",
      "id": 136129839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The global Drug Abuse Testing Market is set to surge, reaching $12.77 billion by 2033 from $6.64 billion in 2024, experiencing a CAGR of 7.54% between 2025-2033. This growth is driven by rising drug abuse rates, enhanced public awareness, and strict laws. Technological advancements in testing and an increased emphasis on preventative healthcare further boost the market. Key product and service segments include analyzers, rapid testing devices, and laboratory services, with urine tests dominating",
      "url": "https://finnhub.io/api/news?id=7fb19a3884e7caa6c6929cccbbce9cc63449259a8753cad5a3ddeaaabe0e0e43"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Growth ESG Portfolios Q2 2025 Commentary",
    "summary": "U.S. equities persevered through tariff and geopolitical scares to deliver solid gains in the second quarter.",
    "url": "https://finnhub.io/api/news?id=e42660fef5a6086a95719ee8195456f168f81f0b6fa19ab4d2cfb8ac84ba4665",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753855800,
      "headline": "ClearBridge Large Cap Growth ESG Portfolios Q2 2025 Commentary",
      "id": 136128577,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2099106130/image_2099106130.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "U.S. equities persevered through tariff and geopolitical scares to deliver solid gains in the second quarter.",
      "url": "https://finnhub.io/api/news?id=e42660fef5a6086a95719ee8195456f168f81f0b6fa19ab4d2cfb8ac84ba4665"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Thermo Fisher’s Q2 Earnings Call",
    "summary": "Thermo Fisher’s second quarter saw a positive market response, as the company surpassed Wall Street’s revenue and adjusted profit expectations. Management attributed the quarter’s performance to robust growth in pharma and biotech, especially in bioproduction and Pharma Services, alongside strong execution in their research and safety market channel. CEO Marc Casper emphasized that “customer uptake is very strong” for the company’s Accelerator Drug Development solution, and highlighted sequentia",
    "url": "https://finnhub.io/api/news?id=410714ccbb92d18b64b72b3f76cd015c7badec3496a93325dd41b2e72f6d2362",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753853510,
      "headline": "5 Insightful Analyst Questions From Thermo Fisher’s Q2 Earnings Call",
      "id": 136129915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher’s second quarter saw a positive market response, as the company surpassed Wall Street’s revenue and adjusted profit expectations. Management attributed the quarter’s performance to robust growth in pharma and biotech, especially in bioproduction and Pharma Services, alongside strong execution in their research and safety market channel. CEO Marc Casper emphasized that “customer uptake is very strong” for the company’s Accelerator Drug Development solution, and highlighted sequentia",
      "url": "https://finnhub.io/api/news?id=410714ccbb92d18b64b72b3f76cd015c7badec3496a93325dd41b2e72f6d2362"
    }
  }
]